206 related articles for article (PubMed ID: 30316985)
1. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
Purcaro C; Vanacore N; Moret F; Di Battista ME; Rubino A; Pierandrei S; Lucarelli M; Meco G; Fattapposta F; Pascale E
Neurosci Lett; 2019 Jan; 690():83-88. PubMed ID: 30316985
[TBL] [Abstract][Full Text] [Related]
2. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
Kaplan N; Vituri A; Korczyn AD; Cohen OS; Inzelberg R; Yahalom G; Kozlova E; Milgrom R; Laitman Y; Friedman E; Rosset S; Hassin-Baer S
J Mol Neurosci; 2014 Jun; 53(2):183-8. PubMed ID: 24633632
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
Oliveri RL; Annesi G; Zappia M; Civitelli D; Montesanti R; Branca D; Nicoletti G; Spadafora P; Pasqua AA; Cittadella R; Andreoli V; Gambardella A; Aguglia U; Quattrone A
Neurology; 1999 Oct; 53(7):1425-30. PubMed ID: 10534246
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.
Soraya GV; Ulhaq ZS; Shodry S; A'raaf Sirojan Kusuma M; Herawangsa S; Sativa MO; Gustaf A; Faridwazdi DAN; Florentia SW; Raisa N; Bintang AK; Akbar M
Neurol Sci; 2022 Jun; 43(6):3649-3670. PubMed ID: 35079903
[TBL] [Abstract][Full Text] [Related]
5. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
8. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
Lee JY; Cho J; Lee EK; Park SS; Jeon BS
Mov Disord; 2011 Jan; 26(1):73-9. PubMed ID: 20945430
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
Comi C; Ferrari M; Marino F; Magistrelli L; Cantello R; Riboldazzi G; Bianchi ML; Bono G; Cosentino M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28125015
[TBL] [Abstract][Full Text] [Related]
10. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
11. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.
Dos Santos EUD; Sampaio TF; Tenório Dos Santos AD; Bezerra Leite FC; da Silva RC; Crovella S; Asano AGC; Asano NMJ; de Souza PRE
J Pharm Pharmacol; 2019 Feb; 71(2):206-212. PubMed ID: 30353564
[TBL] [Abstract][Full Text] [Related]
12. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
Kaiser R; Hofer A; Grapengiesser A; Gasser T; Kupsch A; Roots I; Brockmöller J
Neurology; 2003 Jun; 60(11):1750-5. PubMed ID: 12796525
[TBL] [Abstract][Full Text] [Related]
13. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
Martín-Flores N; Fernández-Santiago R; Antonelli F; Cerquera C; Moreno V; Martí MJ; Ezquerra M; Malagelada C
Mol Neurobiol; 2019 Mar; 56(3):2092-2100. PubMed ID: 29992529
[TBL] [Abstract][Full Text] [Related]
14. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
15. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients.
Lin JJ; Yueh KC; Chang DC; Chang CY; Yeh YH; Lin SZ
J Neurol Sci; 2003 May; 209(1-2):87-92. PubMed ID: 12686408
[TBL] [Abstract][Full Text] [Related]
16. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
18. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
Strong JA; Dalvi A; Revilla FJ; Sahay A; Samaha FJ; Welge JA; Gong J; Gartner M; Yue X; Yu L
Mov Disord; 2006 May; 21(5):654-9. PubMed ID: 16435402
[TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum.
Labrador-Espinosa MA; Grothe MJ; Macías-García D; Jesús S; Adarmes-Gómez A; Muñoz-Delgado L; Fernández-Rodríguez P; Martín-Rodríguez JF; Huertas I; García-Solís D; Mir P
Clin Nucl Med; 2021 Jun; 46(6):e296-e306. PubMed ID: 33782308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
